Serial circulating tumor DNA as a biomarker for monitoring and prognostication in patients with pancreatic cancer

doi:10.3748/wjg.v32.i22.118323

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 32, Issue 22

This Article

(0)

(23)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Observational Study

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Gastroenterol. Jun 14, 2026; 32(22): 118323
Published online Jun 14, 2026. doi: 10.3748/wjg.v32.i22.118323

Table 1 Baseline characteristics of the patients and disease status, n (%)/median (range)

Variable	Resection group, n = 34	Chemotherapy group, n = 105	All patients, n = 139
Age	62 (40-83)	66 (37-82)	65 (37-83)
Sex
Male	16 (47.1)	67 (63.8)	83 (59.7)
Female	18 (52.9)	38 (36.2)	56 (40.3)
Tumor location
Head	19 (55.9)	38 (36.2)	57 (41.0)
Body	9 (26.5)	29 (27.6)	38 (27.3)
Tale	6 (17.6)	25 (23.8)	31 (22.3)
Unknown or multiple	0 (0.0)	13 (12.4)	13 (9.4)
Stage
RPC	13 (38.2)	0 (0.0)	13 (9.4)
BRPC/LAPC	21 (61.8)	34 (32.4)	55 (39.5)
MPC	0 (0.0)	71 (67.6)	71 (51.1)
Metastasis location
Liver	0 (0.0)	56 (53.3)	54 (38.8)
Lung	0 (0.0)	14 (13.3)	14 (10.1)
Peritoneum	0 (0.0)	19 (18.1)	19 (13.7)
Other organs	0 (0.0)	13 (12.4)	13 (9.4)
CA19-9
> 37 U/mL	25 (73.5)	87 (82.9)	112 (80.6)
< 37 U/mL	9 (26.5)	18 (17.1)	27 (19.4)

RPC: Resectable pancreatic cancer; BRPC: Borderline resectable pancreatic cancer; LAPC: Locally advanced pancreatic cancer; MPC: Metastatic pancreatic cancer; CA19-9: Carbohydrate antigen 19-9.

Full Size Table

Citation: Jung K, Lee J, Jang D, Ahn J, Kim B, Yang S, Kim JH, Youn Y, Lee JC, Kim J, Hwang JH. Serial circulating tumor DNA as a biomarker for monitoring and prognostication in patients with pancreatic cancer. World J Gastroenterol 2026; 32(22): 118323
URL: https://www.wjgnet.com/1007-9327/full/v32/i22/118323.htm
DOI: https://dx.doi.org/10.3748/wjg.v32.i22.118323

Jung K, Lee J, Jang D, Ahn J, Kim B, Yang S, Kim JH, Youn Y, Lee JC, Kim J, Hwang JH. Serial circulating tumor DNA as a biomarker for monitoring and prognostication in patients with pancreatic cancer. World J Gastroenterol 2026; 32(22): 118323 [DOI: 10.3748/wjg.v32.i22.118323]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.